J Am Coll Cardiol
January 1992
Although amiodarone is an effective drug for the treatment of life-threatening ventricular arrhythmias, no standard oral loading dose protocol has been defined, and patients often undergo prolonged hospitalization for amiodarone loading. High dose (greater than 1,800 mg/day) oral loading has usually been reserved for unstable patients with incessant ventricular tachyarrhythmias. The current study was designed to 1) examine the clinical and electrophysiologic effects of a high dose oral amiodarone loading regimen in more stable patients; and 2) ascertain its safety and tolerance, possibly allowing shortened amiodarone loading periods and potentially decreased length of hospital stay.
View Article and Find Full Text PDFIntravenous amiodarone was administered to 22 patients with recurrent ventricular tachycardia failing an average of 3.0 prior antiarrhythmic agents after a mean of 14.6 cardioversions per patient.
View Article and Find Full Text PDFThe role of the signal-averaged ECG was prospectively assessed in 517 patients in whom there was a suspicion for malignant ventricular arrhythmias. Patients were divided into Group I with a normal surface QRS width less than 120 ms (426 patients) and Group II with a prolonged QRS duration greater than or equal to 120 ms (91 patients). Late potentials were present in 42 (10%) Group I patients and in 24 (26%) Group II patients.
View Article and Find Full Text PDFPacing Clin Electrophysiol
September 1990
False inhibition of ventricular output due to spurious signals from a bipolar Oscor Medical lead (PY58BV) is reported following implantation of a Pacesetter Synchrony DDDR 2020T. Telemetered bipolar and distal unipolar intracardiac electrograms revealed 20 mV spurious signals coming from the distal screw-in electrode. Reprogramming the sensing channel to unipolar ring prevented inhibition of pacemaker output.
View Article and Find Full Text PDFOur experience with amiodarone therapy in 145 consecutively referred patients with medically refractory sustained ventricular tachycardia and/or fibrillation treated for at least 3 years was reviewed. Ninety-seven had sustained ventricular tachycardia; the remaining 48 patients were survivors of sudden cardiac death. The patients had a mean of 3.
View Article and Find Full Text PDF